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Background: Remission of diabetes is seen in more than 60% of patients after bariatric surgery. There is extensive
variability in the remission rates between different surgical procedures. We analyzed our database and aimed to
develop an easy scoring system to predict the probability of diabetes remission after two surgical procedures
i.e. Ileal Interposition coupled with Sleeve Gastrectomy (IISG) or Diverted Sleeve Gastrectomy (IIDSG).
Methods: In this retrospective study, we analyzed records pertaining to patients who underwent IISG (n = 46) and
IIDSG (n = 29). The primary outcome measure was diabetes remission (A1c <6.5% and not requiring hypoglycemic
drugs). We identified seven preoperative clinical variables (age, duration of diabetes, body mass index, micro and
macrovascular complications, use of insulin and stimulated C-peptide) based on our previous reports to be included
in the diabetes remission score (DRS). The DRS score (7 – 14) was compared between the patients with and without
remission in both the surgery groups.
Results: Mean DRS in patients who underwent IISG was 9.2 ± 1.4. Twenty one (46%) had a remission in diabetes.
DRS was significantly lower in patients with remission than patients without remission (8.1 ± 0.8 versus 10.2 ± 0.9,
p < 0.0001). Mean DRS in patients who underwent IIDSG was 10.4 ± 1.3. Twenty one (72%) had a remission in diabetes.
DRS was significantly lower in patients with remission than patients without remission (9.7 ± 0.8 versus 12.0 ± 0.5,
p < 0.0001). Patients with a DRS ≥ 10 in IISG group and more than 12 in IIDSG group did not get into remission.
Conclusion: Preoperative DRS can be a useful tool to select the type of surgical procedure and to predict the
postoperative diabetes remission.
Trial registration: NCT00834626.
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Bariatric surgery in patients with type 2 diabetes is known
to produce remission in a majority of cases. The improve-
ment is not limited to diabetes alone and includes hyper-
tension, dyslipidemia and obstructive sleep apnea as well.
The magnitude and onset of this improvement outweighs
the weight loss leading to the concept of ‘metabolic sur-
gery’ rather than bariatric surgery [1]. The observed meta-
bolic benefits lead to the extension of this concept to non* Correspondence: hariendo@rediffmail.com
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primarily divided into restrictive and malabsorptive types.
The most common surgical procedures are sleeve gas-
trectomy (SG), gastric banding, Roux-en-Y-Gastric Bypass
(RYGB) and Jejuno-Ileal Bypass (JIB). The observed remis-
sion in diabetes after these surgeries is reported to range
between 45-95% [6].
The standard procedures have been modified to achieve
maximum remission with minimal long term complications.
The modified surgical techniques are Ileal Interposition (II),
Diverted Sleeve Gastrectomy (DSG), Sleeve Gastrectomy
with Duodeno-jejunal Bypass (SG +DJB), Mini-Gastric By-
pass (MGB) and Single Anastomosis Duodeno-Ileal (SADI)td.; licensee BioMed Central Ltd. This is an Open Access article distributed under
n License (http://creativecommons.org/licenses/by/4.0), which permits
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procedures due to the differences involved in patients and
the spectrum of diabetes. The proposed predictive factors
for remission and other outcomes includes age, diabetes
duration, insulin reserve& requirement, body mass index
(BMI), ethnicity and number of preoperative medications
required to manage blood glucose [7-12]. We observed a
significant variability in the remission rates using IISG and
IIDSG as reported previously [13-17]. A good predictive
model is essential in helping the patients and clinicians to
decide about the probability of remission based on pre-
operative criteria. We developed a novel scoring system
known as Diabetes Remission Score (DRS) based on the
previous database. Our intention is to develop a simple,
effective and useful method to help the surgical teams in
predicting the diabetes remission rates postoperatively.
Methods
The present study is a retrospective analysis of all the
patients with poorly controlled type 2 diabetes mellitus
(T2DM), who were subjected to the laparoscopic proce-
dures of IISG or IIDSG at Kirloskar Hospital, Hyderabad,
India. IISG was started in February 2008 and IIDSG was
started in March 2010 and the study was duly approved
by the hospital’s ethics committee (Institutional Review
Board, Kirloskar Hospital, Hyderabad) and registered
(NCT00834626). Informed consent was obtained from all
patients participating in the study. Study participants were
explained specifically about the benefits pertinent to
nonobese subjects and the potential risks involved. The
patient selection criteria and surgical techniques have
been described in detail previously (13 – 17). Briefly, we
included patients having T2DM of more than 1 year
duration (>5 years duration for IIDSG), aged between 25
and 70 years, poor glycemic control with HbA1C > 7% on
the optimum dosage of insulin ± oral hypoglycemic agents
(OHA), stable weight, BMI ≥20 kg/m2 (>18.5 kg/m2 for
IIDSG) and stimulated C-peptide level >1.5 ng/ml. The
decision of mode of surgery (IISG or IIDSG) was taken by
the surgical team in consultation with the endocrinologist
and the patient’s preference. The study is a retrospective
analysis of the patients profile precluding the possibility
of random allocation into each group. We excluded pa-
tients with type 1 diabetes mellitus, undetectable fasting
C-peptide, ketoacidosis in past 6 months, pregnancy




The surgical procedure involved the creation of a 170-cm
segment of ileum, starting at 30 cm proximal to the
ileo-cecal junction. This segment was interposed into the
jejunum, which was divided between 20 and 50 cm fromthe ligament of Treitz. All three anastomoses were
performed side by side with an endo-GIA stapler (Ethicon
Endo-surgery, Cincinnati, OH, USA). A variable sleeve
gastrectomy was performed after devascularization of the
greater curvature from the antrum to the fundus area as
shown in Figure 1. The lumen of the stomach was ad-
justed by a 32–60 French calibrator (Romsons Inter-
national, New Delhi, India) that was placed along the
lesser curvature. The size of the bougie is determined for
each patient individually depending on the baseline body
weight, BMI and the anticipated amount of weight loss.
The size between 32 F to 38 F was used in majority of the
patients. The endo-GIA stapler with 60-mm cartridges
were used for resection. Nonobese patients were subjected
to only fundectomy, leaving a good volume of residual
stomach for normal food intake. The fundectomy was
carried by removing the fundus and with the proximal
limit of dissection 3 cm to cardia.IIDSG
A variable sleeve gastrectomy was performed after devas-
cularization of the greater curvature from the antrum to
the fundus area as described above. The duodenum was
transected using a 60-mm linear stapler with a blue
cartridge. The role of surgical stapler is to provide tissue
approximation and hemostasis without leading to necrosis
and destruction. The tissue thickness varies in the stom-
ach and it is important to select the most appropriate
staple cartridge to accommodate the underlying tissue
[18]. The staple cartridges are color coded as gray, white,
blue, gold, green and black in the ascending order of
closed staple height dimensions. The gastric pouch and
proximal duodenum were then transposed through a
window created at the root of the transverse mesocolon. A
distal ileal segment of 170 cm was transected along with
its mesentery pedicle, measured 30 cm proximal to the
ileocecal valve. Continuity of small bowel is restored by
ileo-ileal anastomosis and the proximal end of this trans-
ected ileal segment was anastomosed to the proximal
duodenum as shown in Figure 2. A point in the jejunum
50 cm from the ligament of Treitz was measured and
anastomosed to the distal part of the interposed ileum,
side to side, using stapler.
Post operatively each participant was followed up at 1,
3, 6 ,9 and 12 months in the 1st year and every 6 months
thereafter. They were subjected to clinical and biochem-
ical assessment. HbA1C <6.5% (without requiring any
medication for diabetes control) was defined as the cri-
terion for remission in diabetes. Our study protocol was
started in 2008 and the ADA defined diabetes remission
into partial and complete in 2009 [19]. Hence, our defin-
ition is similar to that of partial remission given by the
ADA.
Figure 1 Schematic diagram of Ileal Interposition with Sleeve Gastrectomy.
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All outcome measures were evaluated prospectively
from the third month onward at every visit. The seven
variables to be included in the DRS have been derived
from our previous reports. The details of the DRS com-
ponents are given in Table 1. DRS was calculated in all
the patients retrospectively and compared between IISG
and IIDSG procedures. We used Graphpad Quickcalcs
software (Graphpad Software Inc, La Jolla, CA, USA) for
statistical calculations. The continuous variables were
described in the form of mean ± standard deviation and
comparison between the groups was done using un-
paired student’s t test. All tests were two sided and a p
value less than 0.05 were considered significant.
Results
Forty six patients underwent IISG and 29 patients under-
went IIDSG surgical procedures. The baseline demo-
graphic parameters are shown in Table 2 and the operation
details in Table 3. Mean DRS in patients who underwent
IISG (n = 46) was 9.2 ± 1.4 (Range: 7–13). Twenty one
(46%) had a remission in diabetes. In the same group, pa-
tients with BMI ≥ 35 kg/m2, had a remission rate of 85%.
Their mean DRS was 8.9 ± 1.7 versus mean DRS of 9.5 ±
1.1 in patients with BMI less than 35 (p = 0.07). DRS was
significantly lower in patients with remission than patientswithout remission (8.1 ± 0.8 versus 10.2 ± 0.9, p < 0.0001).
All the patients with DRS 7–8 achieved remission of
diabetes, while only 35% patients with DRS 9 had diabetes
remission. There was no remission in diabetes in patients
with baseline DRS ≥ 10 in IISG group as shown in Table 4.
Mean DRS in patients who underwent IIDSG (n = 29)
was 10.4 ± 1.3 (Range: 8–14, significantly higher than II +
SG group, p = 0.0004). Twenty one (72%) had a remission
in diabetes. DRS was significantly lower in patients with
remission than patients without remission (9.7 ± 0.8 versus
12.0 ± 0.5, p < 0.0001). All the patients with DRS 8–10
achieved remission, while 55% patients with DRS 11 had
diabetes remission. There was no remission in diabetes in
patients with baseline DRS ≥ 12.
Patients with DRS ≥ 10 in IISG group and DRS ≥ 12 in
IIDSG group did not get into remission. DRS was not sig-
nificantly different (p = 0.1468) in patients without remis-
sion in IISG (10.2 ± 0.9) versus patients with remission in
IIDSG (9.7 ± 0.8). In patients with IIDSG, intraoperative
complications were observed in 4 patients. One patient
had a dusky duodenal stump leading to application of the
drain. Another patient had a suture-passer tip breakage
into the abdominal wall which was extricated by C arm. A
2 cm opening at the gastric antrum in another patient was
closed in 3–0 PDS because of faulty stapling and the last
patient had ileal perforation managed by exploratory
Figure 2 Schematic diagram of Ileal Interposition with Diverted
Sleeve Gastrectomy.
Table 2 Comparison between 2 groups regarding the
clinical profile and complications




Age years 51.7 (13.3) 57.6 (11.5)
Sex M:F 29 : 17 20 : 9
BMI Kg/m2 23.4 (4.5) 25.6 (4.5)
DM duration Years 9.9 (4.8) 10.1 (5)
Duration of insulin use Years 3.3 (2.9) 3.6 (2.8)
Daily Insulin dose Units 28.2 (10.6) 75.5 (12)
Daily Insulin dose U/Kg 0.45 (0.15) 1.1 (0.1)
Retinopathy Number 21 13
Acanthosis Grade 0.83 (0.9) 1.1 (0.8)
HbA1c % 8.1 (0.59) 9 (0.78)
HDL cholesterol mg/dL 40.2 (5.7) 41 (5)
LDL cholesterol mg/dL 92.7 (18.5) 96 (18.9)
Triglycerides mg/dL 106.7 (37.2) 107 (44)
Serum Iron μg/dL 104.5 (22.4) 112.1 (18.7)
Serum Ferritin ng/mL 44.7 (18.5) 53.3 (12.2)
Vitamin B12 pg/mL 423.3 (102.4) 397.9 (92.9)
Mean (S.D).
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up, none of these patients had any complications with
regard to the intraoperative and immediate postoperative
events.
Discussion
Our study focuses on the development of a novel score
(DRS) preoperatively in predicting diabetes remission
following IISG or IIDSG. DRS was derived from the
variable factors predicting the remission in diabetes. Our
previous studies on IISG have demonstrated duration of
diabetes, BMI and stimulated C-peptide response asTable 1 Diabetes Remission Score Calculator
Parameter Score
1 2
Age (yr) 30 – 60 < 30 or >60
Body Mass Index (kg/m2) ≥ 27 < 27
Duration of T2DM (yr) < 10 ≥ 10
Microvascular complications No Yes
Macrovascular complications No Yes
Preoperative Insulin use No Yes
Stimulated C-peptide (ng/mL) ≥ 4 < 4baseline parameters of response [14,15]. Previous studies
of RYGB reported that old age, longer duration of
diabetes, lower C-peptide level, and lower BMI reduce
the likelihood of response to surgery [7,20,21]. In type 2
diabetes patients with duration of diabetes < 5 years, a
resolution of the disease was obtained in 95%, whereas the
rate of resolution was only 75% and 54% in those who had
type 2 diabetes for 6–10 or >10 years [5]. Scopinaro et al.
has shown that metabolic surgery is less effective in indi-
viduals with lower BMI [22,23]. Insulin resistance is a
major contributing factor for diabetes in patients with
high BMI, whereas beta cell dysfunction predominates in
the normal weight individuals. Hence, the benefits of
metabolic surgery are observed more in obese individuals
when compared to nonobese patients. Our data also
showed similar results in both the groups as shown
in Table 4. IIDSG gives augmented stimulus to theTable 3 Comparison between 2 groups regarding the
surgical procedure and complications




Operation time Hours 3.8 (0.9) 5.8 (0.8)
Hospital stay Days 4.2 (0.8) 5.4 (1.2)
Duration of follow up Months 30.2 (9.6) 12.7 (5.3)
Intraoperative complications Number Nil 4*
Postoperative complications Number Nausea - 12 Nausea – 6
Long term complications Number Nil B12 deficiency – 3
Data given as mean (S.D) * Explained in the results section.
Table 4 Comparison between the groups according to their body mass index
IISG group (N = 46) IIDSG group (N = 29)
Obese Non Obese Obese Non Obese
Number of Patients No 32 14 21 8
Remission of DM No (%) 17 (53) 4 (47) 16 (55) 5 (45)
Baseline BMI kg/m2 31.2(4.7) 24.7(5.3) 33.5(2.6) 25.3(1.4)
BMI at end point kg/m2 27.1(4.8) 23.5 (6.4) 27.5(4.6) 22.9 (5.1)
Δ Body weight kg 9.7 (6.6) 1.4(2.3) 7.8(5.4) 2.2 (1.7)
DRS Score 8.1 (0.8) 10.2 (0.9) 9.7 (0.8) 12 (0.5)
BMI Body Mass Index, Δ Body weight Change in the weight from baseline, DRS Diabetes Remission Score.
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diabetes. The baseline body weight and the amount of ex-
cess body weight lost determine the benefit rates in dia-
betes resolution. Previous reports suggest that diabetes
remission is seen in 60% of patients with restrictive proce-
dures and up to 80 – 90% in combined (restrictive and
malabsorptive) procedures [6,23]. Advanced age is an im-
portant consideration for patient selection also, because of
the augmented risks with surgery and weight loss [24,25].
DRS was significantly lower in patients with remission
than patients without remission. This demonstrates that
patients with lower baseline DRS have better remission
rates and patients with DRS of 7–8 should only be
subjected to IISG. Our data demonstrate that IIDSG may
be taken up for patients with a DRS up to 11. Additionally
DRS was not significantly different (p = 0.1468) in patients
without remission in IISG (10.2 ± 0.9) versus patients with
remission in IIDSG (9.7 ± 0.8). This indirectly suggests
that IIDSG instead of IISG would have helped them in
achieving remission.
IIDSG is more beneficial over the conventional IISG
procedure due to the following points. The IIDSG
excludes the duodenum, leading to attenuated release of
Rubino’s factor (anti-incretin factor, which promotes insu-
lin resistance) and Gastric Inhibitory Polypeptide (GIP)
[26]. Disruption or attenuation of GIP action is associated
with decreased glucagon release, diminished weight gain,
resistance to diet-induced obesity, and improved insulin
sensitivity in preclinical studies [27-30], whereas genetic
variation within the human Gastric Inhibitory Polypeptide
Receptor (GIPR) gene is linked to control of postprandial
glucose and body weight [31,32]. Exclusion of duodenum
also leads to abolition of hedonic (pleasure) value of food,
resulting in lesser indulgence in feeding [33]. In compari-
son to IISG, the interposed ileal segment is shifted more
proximally in IIDSG, leading to augmented glucagon like
peptide (GLP-1) hormone secretion [16,17]. Our surgical
technique has no risk of malabsorptive complications as
the procedure does not involve removal of either intestinal
digestive or absorptive surface. The previous published
long term follow up studies using this technique also
did not report any malabsorptive complications. Ironmalabsorption is theoretically possible due to lack of
gastric intrinsic factor after the surgery. However, we
prescribed supplemental iron to all patients postopera-
tively preventing this complication.
The surgical technique used in this study is designed
essentially for diabetes control and utilizes both the foregut
and hindgut mechanisms [34]. The SG component re-
stricts calorie intake and reduces ghrelin [35]; it also speeds
up gastric transit of food, reaching the ileal segment faster.
The GLP-1 response is defective in T2DM leading to
diminished first phase of insulin secretion [36]. The ileal
interposition helps in the rapid stimulation of ileal segment
by ingested food leading to augmented GLP-1 secretion
[13-15]. GLP-1 also influences glucose metabolism by
inhibiting glucagon secretion, decreasing hepatic gluconeo-
genesis, delaying gastric emptying, promoting satiety,
suppressing appetite, and stimulating glycogenesis [37-43].
We propose a baseline assessment of DRS as a pos-
sible predictor of remission in diabetes following IISG or
IIDSG. The DRS may be divided into 3 grades as grade
1 (mild, DRS 7–8), grade 2 (moderate, 9–11) and grade
3 (severe, DRS 12–14). Higher scores indicate a dimin-
ished chance of achieving remission in a given patient.
The advantages of DRS include an easy clinically rele-
vant score, combining multiple factors affecting the
diabetes and give an objective measure for comparison
between the procedures. Our study has certain limita-
tions. The study analysis and the development of DRS
were based on retrospective observational analysis of the
data. The DRS score was developed based on the data
from sleeve gastrectomy and ileal interposition. Hence,
DRS may not be useful for predicting remission of other
bariatric or metabolic procedures. The status of obesity
alone as a determinant of metabolic surgery is incorrect
due to the identification of a phenotype called metabol-
ically obese and normal weight individuals [44]. This
also limits the wide application of this scoring system
prior to the surgery. The study was inadequately pow-
ered to give a definite conclusion due to limited number
of the patients and mixed population in each group.
Moreover, our data from a single center may not repre-
sent the entire diabetes population of India.
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Diabetes remission score is a useful tool for predicting
the remission in patients with type 2 diabetes undergo-
ing IISG or IIDSG. We propose to introduce DRS as a
tool to select the type of surgical procedure and to
predict the postoperative diabetes remission. Further
multicenter studies of patients from various ethnicities
are required to confirm our preliminary observations.
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